| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MAT2A |
| Uniprot No | P31153 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-395aa |
| 氨基酸序列 | MNGQLNGFHEAFIEEGTFLFTSESVGEGHPDKICDQISDAVLDAHLQQDPDAKVACETVAKTGMILLAGEITSRAAVDYQKVVREAVKHIGYDDSSKGFDYKTCNVLVALEQQSPDIAQGVHLDRNEEDIGAGDQGLMFGYATDETEECMPLTIVLAHKLNAKLAELRRNGTLPWLRPDSKTQVTVQYMQDRGAVLPIRVHTIVISVQHDEEVCLDEMRDALKEKVIKAVVPAKYLDEDTIYHLQPSGRFVIGGPQGDAGLTGRKIIVDTYGGWGAHGGGAFSGKDYTKVDRSAAYAARWVAKSLVKGGLCRRVLVQVSYAIGVSHPLSISIFHYGTSQKSERELLEIVKKNFDLRPGVIVRDLDLKKPIYQRTAAYGHFGRDSFPWEVPKKLKY |
| 预测分子量 | 45.2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
nan
**Background of MAT2A Recombinant Protein**
Methionine adenosyltransferase 2A (MAT2A) is a key enzyme responsible for catalyzing the formation of *S*-adenosylmethionine (SAMe), a universal methyl donor critical for methylation reactions, polyamine synthesis, and redox balance. Unlike its isoform MAT1A, which is predominantly expressed in the liver, MAT2A is widely distributed in extrahepatic tissues and proliferating cells, playing a vital role in cellular metabolism and epigenetic regulation. MAT2A converts methionine and ATP into SAMe, which fuels methylation processes affecting DNA, proteins, and lipids, thereby influencing gene expression, signal transduction, and cell cycle progression.
Dysregulation of MAT2A is implicated in various diseases, particularly cancers. Overexpression of MAT2A is observed in multiple malignancies, where it supports rapid cell proliferation by sustaining SAMe-dependent pathways. This makes MAT2A a promising therapeutic target. Small-molecule inhibitors of MAT2A, such as AG-270 and IDE397. are under investigation for cancers with methylthioadenosine phosphorylase (MTAP) deletions, where MAT2A inhibition disrupts methionine metabolism, selectively targeting tumor cells.
Recombinant MAT2A proteins are engineered using expression systems like *E. coli* or mammalian cells, often fused with tags (e.g., His-tag) for purification. These proteins retain enzymatic activity and structural integrity, enabling biochemical studies, inhibitor screening, and structural analyses (e.g., X-ray crystallography). Recombinant MAT2A is essential for elucidating enzyme kinetics, regulatory mechanisms (e.g., allosteric regulation by SAMe), and interactions with binding partners.
In summary, MAT2A recombinant protein serves as a vital tool for advancing research into methionine metabolism, cancer biology, and drug discovery, offering insights into therapeutic strategies targeting SAMe-dependent pathways.
×
